首页> 外文OA文献 >PTU-157 Her2 Positivity in upper Gastrointestinal Tumours in a Large Multi-Centre UK Cohort Identifies Similar Positivity Rates but different Trends than Previously Reported and Suggests new Potential Avenues for her2 Therapies

【2h】

PTU-157 Her2 Positivity in upper Gastrointestinal Tumours in a Large Multi-Centre UK Cohort Identifies Similar Positivity Rates but different Trends than Previously Reported and Suggests new Potential Avenues for her2 Therapies

机译：PTU-157大型胃肠肿瘤中的PTU-157阳性在大型多中心英国队列中鉴定了类似的积极率，但趋势不同，而不是先前报道，并为HER2疗法提出了新的潜在途径

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
M A Butt; M Gandy; R J Haidry; E S Bloom; S Mackie; M S Khan; J Louis-Auguste; D Oukrif; S-U-R Khan; R Saraswati; M R Banks; M Rodriguez-Justo; L B Lovat; M Novelli;
展开▼
作者单位

展开▼
年度 2013
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. In a cohort of breast cancer screened patients the proportion of HER2 positive cases is lower than that earlier reported and pathological characteristics differ between HER2 3+and HER2 2+/Her2 amplified cases [J] . Giuliani Silvia, Ciniselli Chiara Maura, Leonardi Elena, Virchows Archiv: an international journal of pathology . 2016,第1期

机译：在一组乳腺癌筛查患者中，HER2阳性病例的比例低于先前报道的病例，并且HER2 3+和HER2 2 + / Her2扩增病例的病理特征有所不同
2. EORTC-1203-GITCG - the “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group [J] . Anna Dorothea Wagner, Heike I. Grabsch, Murielle Mauer, BMC Cancer . 2019,第1期

机译：EORTC-1203-GITCG-“创新”试验：单纯化疗与化疗加曲妥珠单抗相比，与化疗加曲妥珠单抗加培妥珠单抗在围手术期治疗HER2阳性，胃和胃食管交界处腺癌对病理反应率的影响：随机阶段EORTC-胃肠道癌组，韩国癌症研究组和荷兰上消化道癌组的II组间试验
3. Amsterdam 70-gene profile (MammaPrint) low risk, even in the HER2 positive subset, identifies a population of women with lower early risk for recurrence despite low response rates to chemotherapy and to HER2 targeted therapy [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：Amsterdam 70-基因型（MammaPrint）低风险，即使在HER2阳性子集中，也识别出患有早期患者的妇女患者，尽管化疗低应对率和HER2靶向治疗
4. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
5. The Use and Enhancement of Anti-Cancer Vaccine Therapy with Low-Toxicity Drugs for the Treatment of HER2 Positive Breast Cancer [D] . Oechsle, Crystal Mae 2019

机译：低毒药物抗癌疫苗治疗在HER2阳性乳腺癌治疗中的应用和增强
6. EORTC-1203-GITCG - the INNOVATION-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab versus chemotherapy plus trastuzumab plus pertuzumab in the perioperative treatment of HER2 positive gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group Korean Cancer Study Group and Dutch Upper GI-Cancer group [O] . Anna Dorothea Wagner, Heike I. Grabsch, Murielle Mauer, 2019

机译：EORTC-1203-GITCG-创新试验：单纯化疗与化疗加曲妥珠单抗相比与化疗加曲妥珠单抗加帕妥珠单抗在围手术期治疗HER2阳性胃和胃食管交界处腺癌对病理反应率的影响：随机阶段EORTC-胃肠道癌组韩国癌症研究组和荷兰上消化道癌组的II组间试验
7. EORTC-1203-GITCG - the “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group [O] . Anna Dorothea Wagner, Heike I. Grabsch, Murielle Mauer, 2019

机译：EORTC-1203-GITCG - “创新”-Trial：单独的化疗与化疗加上曲妥珠单抗，与化疗加曲妥珠单抗Plus Pertuzumab在病理反应率上的围手术期治疗中：随机阶段II-族胃肠道癌组，韩国癌症研究组和荷兰上GI-癌组的IN-CONTGROUP试验

PTU-157 Her2 Positivity in upper Gastrointestinal Tumours in a Large Multi-Centre UK Cohort Identifies Similar Positivity Rates but different Trends than Previously Reported and Suggests new Potential Avenues for her2 Therapies

著录项

相似文献

相关主题

期刊订阅